Prenatal exposure to solvents and fetal outcomes in a Canadian pregnancy cohort

被引:0
|
作者
Ashley-Martin, Jillian [1 ]
Marro, Leonora [1 ]
Kabasakal, Muzeyyen [1 ]
Macpherson, Susan H. [1 ]
Borghese, Michael M. [1 ]
Gaudreau, Eric [2 ]
Provencher, Gilles [2 ]
Arbuckle, Tye E. [1 ]
Fisher, Mandy [1 ]
机构
[1] Hlth Canada, Environm Hlth Sci & Res Bur, Ottawa, ON K1A 0K9, Canada
[2] Inst Natl Sante Publ Quebec INSPQ, Ctr Toxicol Quebec CTQ, Quebec City, PQ G1V 5B3, Canada
基金
加拿大健康研究院;
关键词
Solvents; n-Methyl-2-pyrrolidone; n-Ethyl-2-pyrrolidone; Pregnancy; Fetal loss; Preterm birth; ORGANIC-SOLVENTS; OCCUPATIONAL-EXPOSURE; N-METHYL-2-PYRROLIDONE; N-ETHYL-2-PYRROLIDONE; BIRTH; ELIMINATION; GROWTH; MALES; TIME; RISK;
D O I
10.1016/j.ijheh.2025.114541
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The solvents N-methyl-2-pyrrolidone (NMP) and N-ethyl-2-pyrrolidone (NEP) are established developmental toxicants; however, epidemiological data are lacking. We quantified associations between urinary NEP and NMP metabolites concentrations and pregnancy outcomes in participants enrolled in the pan-Canadian Maternal-Infant Research on Environmental Chemicals study (n = 1865) (2008-2011). Using discrete time survival analysis and logistic regression, we calculated the odds of preterm birth (PTB) and fetal loss. We used multivariable linear regression to quantify associations between metabolites and birth weight z-scores. Participants with quantifiable concentrations of the NEP metabolite 5-hydroxy-N-ethyl-2-pyrrolidone (5-HNEP) had a 41% increased odds of PTB (95% CI: 0.92-2.17). An interquartile range increase in concentrations of the NMP metabolite 5-hydroxy-Nmethyl-2-pyrrolidone (5-HNMP) was associated with a reduced odds of fetal loss (OR = 0.51 95% CI: 0.30,0.89). All other effect estimates were centered around the null value. We report widespread, low-level exposure to NMP metabolites yet no evidence of adverse effects on fetal health. Our analysis of fetal loss was most likely subject to selection bias resulting from conditioning on pregnancies with available first trimester urine samples Our finding that 5-HNEP exposure may increase risk of preterm birth provides impetus for further biomonitoring and etiological research in a pregnant population with contemporary NEP exposure.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Fetal fraction in noninvasive prenatal testing and adverse pregnancy outcomes
    Prensky, Lawrence M.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2024, 231 (01) : e55 - e55
  • [22] Pregnancy and Fetal Outcomes Following Exposure to Modafinil and Armodafinil During Pregnancy
    Kaplan, Sigal
    Braverman, Debra L.
    Frishman, Ilana
    Bartov, Netta
    JAMA INTERNAL MEDICINE, 2021, 181 (02) : 275 - 277
  • [23] Mirtazapine exposure in pregnancy and fetal safety: A nationwide cohort study
    Ostenfeld, Anne
    Petersen, Tonny Studsgaard
    Pedersen, Lars Henning
    Westergaard, Hanne Brix
    Lokkegaard, Ellen Christine Leth
    Andersen, Jon Traerup
    ACTA PSYCHIATRICA SCANDINAVICA, 2022, 145 (06) : 557 - 567
  • [24] Prenatal exposure to environmental phenols and fetal growth across pregnancy in the LIFECODES fetal growth study
    Bommarito, Paige A.
    Stevens, Danielle R.
    Welch, Barrett M.
    Meeker, John D.
    Cantonwine, David E.
    Mcelrath, Thomas F.
    Ferguson, Kelly K.
    ENVIRONMENT INTERNATIONAL, 2024, 190
  • [25] Prenatal marijuana exposure and neonatal outcomes: a retrospective cohort study
    Jones, Michael James
    Lotfi, Asma
    Lin, Amber
    Gievers, Ladawna L.
    Hendrickson, Robert
    Sheridan, David C.
    BMJ OPEN, 2022, 12 (09):
  • [26] Fetal fraction in noninvasive prenatal testing and adverse pregnancy outcomes: a response
    Becking, Ellis C.
    Sistermans, Erik A.
    Bekker, Mireille N.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2024, 231 (01) : e56 - e56
  • [27] Pregnancy and fetal outcomes following paternal exposure to glatiramer acetate
    Kaplan, Sigal
    Dragut, Claudia
    Ghimpeteanu, Andra
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 525 - 525
  • [28] Pregnancy outcomes after fetal exposure to antithyroid medications or levothyroxine
    Schurmann, Lene
    Hansen, Anne Vinkel
    Garne, Ester
    EARLY HUMAN DEVELOPMENT, 2016, 101 : 73 - 77
  • [29] Pregnancy and fetal outcomes following maternal exposure to glatiramer acetate
    Kaplan, Sigal
    Zeygarnik, Mikhail
    Stern, Tali
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 305 - 306
  • [30] Buprenorphine during Pregnancy: Clearance, Fetal Exposure and Neonatal Outcomes
    Coker, Jessica
    McLeod, Cody
    Narayanan, Sreedharan
    David, Thomas
    Ritchie, James
    Mancino, Michael
    Stowe, Zachary
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S422 - S423